The biopharmaceutical industry is in intense conflict over a case that could determine how broadly a patent can cover a cutting edge invention. More than a dozen companies have taken opposite sides in the dispute between Amgen, Inc. and Sanofi over their PCSK9-targeting antibodies.
The US Supreme Court is to hear oral argument in the case, Amgen v. Sanofi, on 27 March. The case focuses on the standard for the enablement requirement in the...